Phaseline

Targets › FGFR2

FGFR2 (Fibroblast growth factor receptor 2): drug programs, companies and trials

38 programs from 36 companies in 87 trials: 54 Phase 2, 25 Phase 1, 8 Phase 3; Oncology, Gastroenterology, Other; next expected readout Nov 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. (UniProt, P21802)

Open in Phaseline: the race on FGFR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TransThera Sciences (Nanjing)TT-00420 (tinengotinib)
Fibroblast growth factor receptor (FGFR) inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 3Cholangiocarcinoma; Cholangiocarcinoma Metastatic; Breast Cancer; Prostate Cancer (CRPC)Dec 2026
ExelixisZanzalintinib (XL092)
Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL
FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRAPhase 3Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma …Dec 2026
Johnson & Johnson (Janssen)Erdafitinib (TAR-210)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 3Urothelial Cancer; Non-Muscle Invasive Bladder Neoplasms; Urothelial Carcinoma; Advanced Malignant Solid Neoplasm …Dec 2026
Taiho OncologyFutibatinib (TAS-120)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Advanced Cholangiocarcinoma; Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Advanced/Metastatic Cancer; Biliary Tract Neoplasms …Dec 2026
Beijing InnoCare Pharma TechICP-192
FGFR2 inhibitor
FGFR2Phase 2Intrahepatic Cholangiocarcinoma (ICC)Dec 2026
Memorial Sloan Kettering Cancer CenterPalifermin
Fibroblast growth factor receptor 2 agonist
FGFR2Phase 2LeukemiaDec 2026
Tianjin Medical University Cancer Institute and HospitalPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Gastrointestinal CancerDec 2026
Shanghai Zhongshan HospitalHRS-4642
FGFR1/2/3/4 inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 2Biliary Tract Cancer; Pancreatic CancerDec 2026
Sameek RoychowdhuryPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Advanced Pancreatic CarcinomaDec 2026
University of UtahPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Relapsed or Refractory B-cell Non-Hodgkin LymphomaMar 2027
UNICANCERPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Solid Tumor, MiscellaneousJun 2027
Mehmet AkcePemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Intrahepatic CholangiocarcinomaJul 2027
National Cancer Institute (NCI)Rogaratinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Locally Advanced Gastrointestinal Stromal TumorJul 2027
Elevar TherapeuticsLirafugratinib
FGFR2 inhibitor
FGFR2Phase 2FGFR2 Gene Fusion/RearrangementSep 2027
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwestbemarituzumab
Fibroblast growth factor receptor 2 inhibitor; Low affinity immunoglobulin gamma Fc region receptor III-A binding agent
FGFR2, FCGR3APhase 2Metastatic Gastro-esophageal AdenocarcinomaSep 2027
Kinaset TherapeuticsFrevecitinib (KN-002)
FGFR2 inhibitor
FGFR2Phase 2Severe AsthmaNov 2027
Ohio State University Comprehensive Cancer CenterPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Locally Advanced Ampulla of Vater CarcinomaDec 2027
Haitao Zhao, MDPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Biliary Tract Cancer (BTC)Dec 2027
Lund University HospitalPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Dedifferentiated LiposarcomaDec 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDonafenib
Multi-kinase inhibitor with activity against FGFRs, VEGFR, and RET
FGFR1, FGFR2, FGFR3, FGFR4Phase 2Hepatocellular CarcinomaJan 2028
National Cancer Center, JapanE7090
FGFR inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 2Advanced or Recurrent Solid TumorsMar 2028
HutchmedHmpl-453 (HMPL-453)
Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor
FGFR1, FGFR2, FGFR3Phase 2Advanced Intrahepatic CholangiocarcinomaJun 2028
Dana-Farber Cancer InstitutePemigatinib (INCB054828)
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2SDH Gene MutationOct 2028
QED Therapeutics, a BridgeBio companyInfigratinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2AchondroplasiaMar 2030
City of Hope Medical CenterPalifermin
Fibroblast growth factor receptor 2 agonist
FGFR2Phase 2Acute Myeloid Leukemia With Complex KaryotypeNov 2031
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDerazantinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Intrahepatic Cholangiocarcinoma–
AstraZenecaFexagratinib (AZD4547)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 1Muscle Invasive Bladder Cancer; Metastatic Breast CancerNov 2026
BeOne MedicinesBG-C137
anti-FGFR2b antibody-drug conjugate
FGFR2Phase 1Advanced Solid TumorDec 2026
OHSU Knight Cancer InstitutePemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 1Acute Myeloid LeukemiaDec 2026
Hangzhou Zhongmei Huadong PharmaceuticalHDM2020
FGFR2b-targeted antibody-drug conjugate
FGFR2Phase 1Squamous Non-small Cell Lung Cancer(NSCLC); Solid TumorJan 2027
Cogent BiosciencesCGT4859
selective FGFR2/3 inhibitor
FGFR2, FGFR3Phase 1Intrahepatic Cholangiocarcinoma (Icc)Mar 2027
Tyra BiosciencesTYRA-200
FGFR 1/2/3 tyrosine kinase inhibitor
FGFR1, FGFR2, FGFR3Phase 1Locally Advanced CholangiocarcinomaMar 2027
EisaiE-7090 (E7090)
Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor
FGFR1, FGFR2, FGFR3Phase 1Hepatic ImpairmentAug 2027
KinoTeck TherapeuticsKNT-0916
FGFR2 inhibitor
FGFR2Phase 1Solid Tumors With FGFR2 Alterations, AdultSep 2027
Massachusetts General HospitalPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 1Advanced Solid TumorDec 2027
Tyra BiosciencesTYRA-430
FGFR inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 1Metastatic Hepatocellular CarcinomaJan 2028
M.D. Anderson Cancer CenterPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 1Advanced CholangiocarcinomaFeb 2028
3H Pharmaceuticals3HP-2827
FGFR2 inhibitor
FGFR2Phase 1Solid Tumors With FGFR2 Alterations, AdultJun 2028

Conditions

Non-Muscle Invasive Bladder Neoplasms (3) Advanced Solid Tumor (3) Colorectal Cancer (3) Solid Tumors With FGFR2 Alterations, Adult (2) Hepatocellular Carcinoma (2) Urothelial Cancer (2) Advanced Malignant Solid Neoplasm (2) Solid Tumor (2) Advanced Cholangiocarcinoma (2) Hepatic Impairment (2) Intrahepatic Cholangiocarcinoma (2) Muscle Invasive Bladder Cancer (1)

Modalities

small molecule (24), mixed (11), antibody (2), protein or peptide (1)

Companies

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (2) Tyra Biosciences (2) KinoTeck Therapeutics (1) AstraZeneca (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Johnson & Johnson (Janssen) (1) Hangzhou Zhongmei Huadong Pharmaceutical (1) Taiho Oncology (1) Shanghai Zhongshan Hospital (1) Elevar Therapeutics (1) Massachusetts General Hospital (1) BeOne Medicines (1) Exelixis (1) UNICANCER (1) QED Therapeutics, a BridgeBio company (1) National Cancer Center, Japan (1) National Cancer Institute (NCI) (1) TransThera Sciences (Nanjing) (1) Mehmet Akce (1) Memorial Sloan Kettering Cancer Center (1)

Related targets

FGFR3 (28) FGFR1 (27) FGFR4 (12) FCGR3A (1) MET (1) KIT (1) PDGFRA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.